论文部分内容阅读
目的:探讨胱天蛋白酶募集域蛋白9（caspase recruitment domain protein 9，Card9）基因多态性与急性胰腺炎（acute pancreatitis，AP）及生长抑素临床疗效的关系。方法:选取2019年6月至2020年5月上海市松江区中心医院就诊的86例AP患者为研究对象，同期选择健康志愿者81名为对照组，进行前瞻性队列研究。查阅国家生物技术信息中心（National Center for Biotechnology Information，NCBI）核苷酸数据库，筛选Card9的10个常见单核苷酸多态性位点。SNapShot微测序法检测Card9单核苷酸多态性位点。AP患者均给予生长抑素治疗，观察Card9单核苷酸多态性与AP患者临床症状、辅助检查指标的关系。正态分布的计量资料两组间比较采用独立样本n t检验；非正态分布计量资料以n M（n Q1，Q3）表示，组间比较应用秩和检验。计数资料组间比较采用n χ2检验。n 结果:AP组患者Card9 rs10870077 C>G单核苷酸多态性位点频率较健康对照组显著增加，差异有统计学意义（n OR=1.934，95%n CI =1.011~3.700，n P=0.046）。与CC基因型相比，Card9 rs10870077 C>G中重症AP患者生长抑素治疗组腹痛腹胀消失时间明显延长［（5.64±2.06）d与（3.76±1.23）d，n t=2.98，n P=0.006］，Card9 rs10870077 C>G重症AP患者生长抑素治疗组住院时间增加［（13.25±5.31）d与（9.00±3.68）d，n t=1.51，n P=0.170］。n 结论:Card9 rs10870077 C>G是AP的易感因素，与重症AP生长抑素临床疗效的个体差异存在一定相关性。“,”Objective:To investigate the relationship between caspase recruitment domain protein 9 (CARD9) gene polymorphism and acute pancreatitis (AP) and the clinical efficacy of somatostatin.Methods:A total of 86 patients with AP treated in Shanghai Songjiang District Central Hospital from June 2019 to may 2020 were selected as the research object, and 81 healthy volunteers were selected as the control group for a prospective cohort study. The nucleotide database of National Center for Biotechnology Information (NCBI) was consulted to screen 10 common single nucleotide polymorphisms of CARD9.The single nucleotide polymorphism of CARD9 was detected by SNapShot micro sequencing. All patients with AP were treated with somatostatin. The relationship between CARD9 single nucleotide polymorphism and clinical symptoms and auxiliary examination indexes was observed.The measurement data of normal distribution were compared by independent sample t-test. The measurement data of non normal distribution are represented by M (Q1, Q3), and the rank sum test is used for comparison between groups. The comparison of counting data between groups was adopted χn 2 inspection.n Results:The frequency of CARD9 rs10870077 C>G SNP in patients of AP group was significantly higher than that in healthy controls (n OR=1.934, 95% n CI=1.011-3.700, n P=0.046). Compared with CC genotype, the disappearance time of abdominal pain and abdominal distension in the somatostatin treatment group of CARD9 rs10870077 C>G moderate and severe AP patients was significantly longer ((5.64±2.06) d and (3.76±1.23) d,n t=2.98, n P=0.006), and the average hospital stay in the somatostatin treatment group of CARD9 rs10870077 C>G severe AP patients was increased by ((13.25±5.31) d and (9.00±3.68) d,n t=1.51, n P=0.170).n Conclusion:CARD9 rs10870077 C>G is a predisposing factor for AP, which is related to the individual differences in the clinical efficacy of somatostatin in severe AP.